PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Large Increase in Short Interest

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 14,823 shares, an increase of 30.8% from the March 15th total of 11,335 shares. Based on an average trading volume of 3,250 shares, the days-to-cover ratio is currently 4.6 days. Approximately 0.1% of the company’s stock are sold short.

PureTech Health Price Performance

Shares of PRTC traded up $0.03 during trading hours on Friday, hitting $18.25. The company had a trading volume of 6,088 shares, compared to its average volume of 4,135. The business has a fifty day moving average of $16.86 and a 200-day moving average of $17.30. PureTech Health has a 12 month low of $14.50 and a 12 month high of $19.92.

Institutional Trading of PureTech Health

A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP grew its position in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Pentwater Capital Management LP owned approximately 0.31% of PureTech Health worth $1,388,000 at the end of the most recent quarter. Institutional investors own 0.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.